Nifuratel/Nystatin

To evaluate whether there is any difference in effectiveness between the nifuratel-nystatin vaginal soft capsules (specification: each capsule contains 0.5 g nifuratel and 200,000 units of nystatin) produced by Jiangsu Zhengrui Pharmaceutical Technology Co., Ltd. and the control drug nifuratel-nystatin vaginal soft capsules Mamicompa® (specification: each capsule contains 0.5 g nifuratel and 200,000 units of nystatin) produced by Pulli Chemical Industry Company and Dopa Pharmaceutical Co., Ltd. of Italy, and to evaluate whether the two preparations are equivalent preparations.

Main purpose: Using nifuratel nystatin vaginal soft capsules (trade name: Maimikangpa®) as a positive control, evaluate the effectiveness of the experimental drug nifuratel nystatin vaginal soft capsules produced by Jiangsu Wangao Pharmaceutical for simple vulvovaginal candidiasis, and evaluate whether the two preparations are equivalent preparations. ? Secondary purpose: Using nifuratel nystatin vaginal soft capsules (trade name: Maimikangpa®) as a positive control, evaluate the safety of the experimental drug nifuratel nystatin vaginal soft capsules for simple vulvovaginal candidiasis.